​Lucius Pharmaceuticals Version of Vibegron Now Available

Lucius Pharmaceuticals Version of Vibegron Now Available

1.Basic Drug Information

Vibegron (generic name: vibegron) is an oral, once-daily β3-adrenergic receptor agonist approved by the FDA in 2020 for the treatment of adult OAB symptoms, and is particularly indicated for men who are concurrently receiving BPH therapy—a distinguishing feature from other OAB medications.

2.Mechanism of Action

The bladder detrusor muscle expresses β3-adrenergic receptors; activation of these receptors induces smooth muscle relaxation, increases bladder capacity, and reduces pressure during the storage phase. Vibegron selectively acts on β3 receptors without interfering with other adrenergic receptor subtypes, thereby minimizing off-target effects such as cardiovascular events. This mechanism directly counteracts detrusor overactivity in OAB.

3.Unique Status

Most currently available OAB drugs are anticholinergics (e.g., tolterodine, solifenacin), which suppress contraction by blocking M receptors but may cause dry mouth, constipation, cognitive impairment, and other side effects. As a β3-agonist, vibegron offers a novel therapeutic pathway and is the "first and only" OAB agent proven to be co‑administered with BPH drugs without increasing drug‑drug interaction risks.

4.Target Population

Clearly indicated for adults, including men and women with urgency, frequency, and urge incontinence; particularly recommended for men who have OAB symptoms despite ongoing BPH treatment. Pediatric safety has not been established.

Understanding Overactive Bladder (OAB)

1.What is Overactive Bladder?

Overactive bladder (OAB) is a lower urinary tract symptom complex characterized by urgency as the core symptom, often accompanied by frequency and nocturia, with or without urge incontinence. It is not a single disease but a comprehensive manifestation of various neuromuscular dysfunctions. In a normal bladder, the detrusor remains relaxed at low pressure during storage; when volume reaches a certain threshold, the brain issues a voiding command. In OAB patients, however, the detrusor contracts involuntarily during the storage phase even with small urine volumes, sending an "urgent evacuation" signal to the brain, resulting in a strong, difficult-to-delay urge to void.

2.Three Core Symptoms of OAB

Urgency: A sudden, compelling desire to pass urine that is difficult to defer; if not promptly addressed, leakage may occur.

Frequency: Voiding ≥8 times per 24 hours, significantly interfering with daily work and sleep.

Urge Incontinence: Involuntary urine leakage accompanying urgency, one of the most distressing symptoms of OAB.

3.Epidemiology and Impact of OAB

Statistics indicate that approximately 10%–15% of adults worldwide are affected by OAB, with prevalence rising with age. However, most patients delay seeking medical help due to embarrassment or the belief that "it’s just part of getting older." This attitude often leads to symptom exacerbation, affecting social life, work, and mental health.

4.Why Proactive Screening is Necessary

OAB is not a normal part of aging but a manageable chronic condition. Self‑recognition involves asking: Do you often suddenly need to rush to the toilet? Do you void more than 8 times per day? Do you leak urine before reaching the toilet? If the answer to any of these is "yes," you should proactively mention it to your doctor.

OAB and BPH

1.Brief Introduction to Benign Prostatic Hyperplasia (BPH)

BPH is a non‑cancerous enlargement of the prostate common in middle‑aged and older men. The hyperplastic gland compresses the urethra, causing mechanical obstruction, manifested as straining to void, weak stream, hesitancy, and sensation of incomplete emptying. Its core problem is "difficulty in voiding," rather than "loss of storage control."

2.Overlapping Symptoms but Distinct Mechanisms

OAB: Erroneous neural signals instruct the bladder to contract when not full, producing an urgent "cannot hold" sensation.

BPH: The enlarged prostate compresses the urethra, producing an obstructive sensation of "wanting to urinate but unable to," often with post‑void dribbling.

Both can present with frequency and nocturia, but OAB frequency stems from increased bladder sensitivity, whereas BPH frequency results from elevated residual urine volume and reduced effective capacity. If treated solely for BPH, OAB symptoms may show no improvement.

3.Diagnostic and Screening Recommendations

Physicians should assess both conditions simultaneously. Commonly used tools include: International Prostate Symptom Score (IPSS), voiding diary, uroflowmetry, and post‑void residual ultrasound. The medications for the two conditions are entirely different—BPH commonly uses α‑blockers or 5α‑reductase inhibitors, while OAB first‑line therapy is β3‑agonists or anticholinergics.

4.Clinical Pitfall

Many men who continue to experience frequency and urgency after taking BPH medications mistakenly believe that "the drug is not potent enough," when in fact they may have an undiagnosed OAB.